BS2011
Below is the excerpt from the announcement dated Feb 2017.
They have exceeded the outcomes of the supplemental
tests with excellent trial results. Can’t wait until they have their meeting with BSI and the oversight committee and this is all sorted.
“Based on information received from BSI, the Company is pleased to advise that CE Certification for the pancreatic cancer indication will now be granted subject to the following conditions:
•Provision of supplemental data from 20 locally advanced pancreatic cancer patients supporting the existing safety and clinical performance data already reviewed,”
BS2011Below is the excerpt from the announcement dated Feb 2017....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.55K | 44.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.48pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |